Institutional & Specialty Sales Consultant - Stroke/Thrombosis | Rockville, MD

Institutional & Specialty Sales Consultant - Stroke/Thrombosis

At Bayer, we're reimagining what's possible in healthcaredriven by our bold mission of "Health for all, Hunger for none." We're launching a dynamic Institutional & Specialty Sales team to bring Asundexian, a next-generation stroke prevention therapy, to market. You, as a Pharmaceutical Sales Representative will have a rare opportunity to shape access, accelerate clinical adoption, and play a pivotal role in a high-profile neurology launchdelivering innovation to patients when it matters most.

This role will cover the geography of Glen Burnie, MD including the following cities:

• Glen Burnie, MD
• Pasadena, MD
• South Baltimore, MD
• Laurel, MD
• Columbia, MD

Candidates must be domiciled within the territory.

Why Join Bayer

• This is an extraordinary opportunity to be part of a new team launching Asundexian, an oral Factor XIa inhibitor.
• Access top-tier compensation, healthcare coverage, and financial security programsincluding a 401(k) with up to 10% company contributions, Employee Stock Purchase Plan, and Retiree Medical Account.
• Receive exceptional family support, including paid parental leave, fertility benefits, and adoption support.
• Employee discount on all Bayer Consumer Health products.
• Robust Performance-driven quarterly incentive.
• Bayer was named one of Fast Company magazine's Most Innovative companies in Medicines and Therapeutics in 2026.
• We are committed to investing in digital tools to allow our team to work smarter and to harness the power of AI.

As an Institutional & Specialty Pharmaceutical Sales Consultant, you will:

• Drive clinical demand, education, and sales by communicating the value of Asundexian in stroke prevention;
• Lead formulary access by navigating P&T committees and influencing protocol adoption across health systems;
• Build strategic relationships with priority institutions, including key stakeholders at the institutions (i.e., C and D Suite and Head of Pharmacy, Head of Quality), and neurologists;
• Develop territory business plans based on local market insights and collaborate with internal teams to support a successful launch;
• Demonstrate expertise and knowledge of disease state, the marketplace, competitors, industry, and cross-functional activities/plans, as well as possessing the analytical rigor to anticipate and identify business opportunities and challenges;
• Analyze competitive landscape and proactively identify opportunities and risks.

Required Qualifications

• Bachelor's degree or 10 years of relevant sales experience in competitive landscapes in lieu of a Bachelor's degree;
• Experience selling into hospitals, health systems, or institutional accounts;
• Strong communication, presentation, and stakeholder engagement skills;
• Ability to meet customer credentialing and safety requirements;
• Valid driver's license with a clean driving record;

Preferred Qualifications

• Advanced degree (Life Sciences, Pharmacy, Business, or related field);
• Proven success in biotech, medical, or pharmaceutical sales in competitive environments, including experience launching new products and product indications;
• Deep understanding and significant experience working in stroke, anti-coagulation, neurology, and cardiovascular therapeutic areas;
• Experience selling in institutional and clinical settings, and navigating the P&T committee process;
• Experience in establishing and pulling-through in-patient to out-patient protocols;

Employees can expect to be paid a salary between $124,320 - $186,480. Additional compensation may include a bonus or commission (if relevant). Additional benefits include health care, vision, dental, retirement, PTO, sick leave, etc.

This salary range is merely an estimate and may vary based on an applicant's location, market data/ranges, an applicant's skills and prior relevant experience, certain degrees and certifications, and other relevant factors.

This posting will be available for application until at least 06/08/2026.